BCMA CAR-T治疗复发难治多发性骨髓瘤后的感染并发症
中位随访6.0个月(95%CI 4.7-7.4)期间29例(53%)发生47次感染事件,以病毒(53%)和细菌(40%)为主,92%为轻中度,68%累及呼吸道,53%发生在输注后100天内。
要点
- BCMA CAR-T后感染以病毒和细菌为主,多为轻中度呼吸道感染
- 半数感染发生在输注后100天内,需加强早期监测
- 尽管免疫抑制因素多,危及生命的严重感染相对少见
核心结论
- BCMA CAR-T治疗复发难治多发性骨髓瘤后感染常见但多为轻中度,严重或危及生命的感染相对较少。
主要发现
- 中位随访6.0个月(95%CI 4.7-7.4),29例(53%)共发生47次感染事件:细菌40%、病毒53%、真菌6%。
- 92%的感染为轻中度,68%累及下呼吸道或上呼吸道,53%发生在CAR-T输注后100天内。
- 淋巴清除前35%患者有严重低丙种球蛋白血症,18%有严重淋巴细胞减少;68%接受桥接化疗;输注后首月98%出现3至4级中性粒细胞减少;输注后1年76%有低丙种球蛋白血症。
关键数值与推荐
- 感染事件构成:细菌40%、病毒53%、真菌6%;严重程度以轻中度为主(92%);部位以呼吸道为主(68%)。
- 未发现统计学显著的感染危险因素;既往治疗线数、桥接化疗、近期感染及CAR-T后淋巴细胞减少为可能危险因素,需进一步探索。
临床怎么用
- BCMA CAR-T后应重点关注输注后100天内的感染监测,尤其呼吸道病毒和细菌感染,并关注低丙种球蛋白血症与淋巴细胞减少的长期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy (BCMA CAR-T) is an effective treatment of relapsed refractory multiple myeloma (MM). However, the pattern of infectious complications is not well elucidated. We performed a single-center retrospective analysis of infection outcomes up to 1 year after BCMA CAR-T for MM from 2018 to 2020. Fifty-five patients with MM were treated with BCMA CAR-T. Before lymphodepletion (LD), 35% of patients had severe hypogammaglobulinemia and 18% had severe lymphopenia. Most patients (68%) received bridging chemotherapy (BC) before LD. In the first month after CAR-T, 98% patients had grade 3 to 4 neutropenia. At 1 year after infusion, 76% patients had hypogammaglobulinemia. With a median follow-up of 6.0 months (95% confidence interval, 4.7-7.4), there were a total of 47 infection events in 29 (53%) patients: 40% bacterial, 53% viral, and 6% fungal. Most (92%) were mild-moderate and of the lower/upper respiratory tract system (68%). Half of the infections (53%) occurred in the first 100 days after CAR-T infusion. Although no statistically significant risk factors for infection were identified, prior lines of therapy, use of BC, recent infections, and post-CAR-T lymphopenia were identified as possible risk factors that need to be further explored. This is the largest study to date to assess infectious complications after BCMA CAR-T. Despite multiple risk factors for severe immunosuppression in this cohort, relatively few life-threatening or severe infections occurred. Further larger studies are needed to better characterize the risk factors for and occurrence of infections after BCMA CAR-T.
引用
- Thiruvengadam SK, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022. PMID: 34543400. doi:10.1182/bloodadvances.2020004079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。